OncoMatch

OncoMatch/Clinical Trials/NCT04131413

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

Is NCT04131413 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies pNGVL4aCRTE6E7L2 for human papillomavirus type 16.

Phase 1RecruitingSidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04131413Data as of May 2026

Treatment: pNGVL4aCRTE6E7L2The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III that is human papillomavirus (HPV) 16+.

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: HPV16 any tested

cervical cytologic samples are HPV16+ by Roche Cobas 4800, Roche Linear Array HPV Genotyping test or other FDA-approved HPV genotyping test

Required: HIV1 any tested (negative)

For the HIV- patient cohort only: patients ... who are HIV negative

Required: HIV1 any tested (positive)

For the HIV+ patient cohort only: patients ... that are HIV positive

Disease stage

Grade: IIIII (CIN)

CIN2/3

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: investigational hpv vaccine

Lab requirements

Blood counts

Absolute neutrophil count > 1,500/mcL; CD4 cell count > 200/mcL; Platelets > 100,000/mcL; Hemoglobin > 10.0 g/dL

Kidney function

Creatinine ≤1.5 x upper institutional limit normal

Liver function

Total bilirubin < 1.5 X upper institutional limit of normal (patients with diagnosed Gilbert's Syndrome will not be excluded if direct bilirubin is within normal institutional limits); AST <1.5 X the upper institutional limit of normal; ALT <1.5 X the upper institutional limit of normal

Participants must have normal organ and marrow function within 45 days of enrollment as defined below: Absolute neutrophil count > 1,500/mcL ... Platelets > 100,000/mcL ... Hemoglobin > 10.0 g/dL ... Total bilirubin < 1.5 X upper institutional limit of normal ... AST <1.5 X the upper institutional limit of normal ... ALT <1.5 X the upper institutional limit of normal ... Creatinine ≤1.5 x upper institutional limit normal

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Alabama at Birmingham · Birmingham, Alabama
  • Johns Hopkins University · Baltimore, Maryland

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify